Zymenex
Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | (19 %) | (73 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | 695 % | 9 % | 16 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | 600 % | 9 % | 12 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 83 % | 78 % | 44 % |
Source: Company filings or news article
Related Content
Zymenex was a Danish biopharmaceutical company founded in 1998, with its headquarters in Hilleroed, Denmark, and research laboratories in Stockholm, Sweden. The company concentrated its research and development efforts on creating pharmaceutical products for rare, genetic, and life-threatening diseases, particularly Lysosomal Storage Diseases, for which no treatments were available. Its business model revolved around the discovery, development, and eventual commercialization of biologic therapeutics, specifically novel enzyme replacement therapies.
The company's primary focus was on addressing unmet medical needs for patients suffering from these debilitating conditions. A significant milestone for Zymenex was the development of Lamazym™ (velmanase alfa), a recombinant enzyme for treating alpha-Mannosidosis. This product received Orphan Drug Designation in both Europe and the US. In 2008, Zymenex sold its lead product at the time, Metazym, intended for Metachromatic Leukodystrophy (MLD), to Shire Pharmaceuticals for $135 million. Following this, the company developed Lamazym and another therapy, Galaczym, for Krabbe's disease.
On August 26, 2013, the Italian pharmaceutical company Chiesi Group announced its acquisition of Zymenex Holding A/S from its largest shareholder, the venture capital firm Sunstone Capital. The acquisition marked Chiesi's entry into the rare disease market, providing it with Zymenex's research and development capabilities in recombinant biologics. Chiesi planned to leverage its global commercial footprint to bring Lamazym to patients worldwide. Following the acquisition, Zymenex was gradually integrated into Chiesi's R&D structure, with Chiesi eventually integrating Zymenex into its Nordic business, Chiesi Pharma AB, in 2018. In 2018, Lamazym, renamed Lamzede®, was granted marketing authorization by the European Medicines Agency.
Keywords: Zymenex, Chiesi Group, biopharmaceutical, rare diseases, genetic diseases, Lysosomal Storage Diseases, enzyme replacement therapy, Lamazym, velmanase alfa, alpha-Mannosidosis, orphan drugs, Sunstone Capital, drug development, Metazym, Galaczym, Krabbe's disease, recombinant biologics, pharmaceutical acquisition, European Medicines Agency, Lamzede